Pre-Emptive Rituximab Treatment for Epstein\textendashBarr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation Is a Worthwhile Strategy in High-Risk Recipients: A Comparative Study for Immune Recovery and Clinical Outcomes
Nicolas Stocker
(1)
,
Myriam Labopin
(2)
,
Inès Boussen
(1)
,
Olivier Paccoud
(2)
,
Agnès Bonnin
(2)
,
Florent Malard
(1, 2)
,
Corinne Amiel
(3)
,
Joël Gozlan
(2)
,
Giorgia Battipaglia
(2)
,
Rémy Duléry
(2)
,
Federica Giannotti
(2)
,
Annalisa Ruggeri
(2)
,
Béatrice Gaugler
(1, 2)
,
Mohamad Mohty
(1, 2)
,
Eolia Brissot
(1, 2)